WO
WITTE OWEN N.
Director
BoardM
Insider track record
Board DirectorAcross 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Browse the complete record of transactions filed by WITTE OWEN N., Director. Director active across 2 companies, notably Allogene Therapeutics, Inc.. Aggregated, 11 disclosures have been logged. Breakdown: 0 buy · 9 sells. Total volume traded: €1.3m. Activity tracked since 9 June 2021. The latest transaction was disclosed on 13 June 2023 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations11 total
74,561 shares0Common StockSEC:0001593968-23-001009:0
10,000 shares@ US$16.5018.9% of flowCommon StockSEC:0001737287-22-000068:0
10,000 shares@ US$16.5018.9% of flowCommon StockSEC:0001737287-22-000069:0
10,000 shares@ US$11.760.016% mcap21.2% of flowCommon StockSEC:0001214659-22-008272:0
22,089 shares0Common StockSEC:0001214659-22-008169:0
5,000 shares@ US$25.540.016% mcap20.5% of flowCommon StockSEC:0001214659-21-009372:0
5,000 shares@ US$25.5426.1% of flowCommon StockSEC:0001214659-21-009372
5,000 shares@ US$23.700.015% mcap19.3% of flowCommon StockSEC:0001214659-21-008900:0
5,000 shares@ US$23.7024.5% of flowCommon StockSEC:0001214659-21-008900
9,969 shares@ US$25.0549.5% of flowCommon StockSEC:0001214659-21-006504
9,969 shares@ US$25.050.030% mcap39.0% of flowCommon StockSEC:0001214659-21-006504:0
About WITTE OWEN N.
Owen N. Witte is a Director at Allogene Therapeutics, Inc., a company specializing in gene therapies. In his role, he contributes to the strategy and governance of the firm, ensuring that Allogene meets industry standards and shareholder expectations.